Literature DB >> 869984

Radiosensitizing and cytocidal effects on hypoxic cells of RO-07-0582, and repair of x-ray injury, in an experimental mouse tumour.

S A Hill, J F Fowler.   

Abstract

The delay in regrowth to 10 mm diameter of a transplanted carcinoma in mice was used to estimate the effect of the hypoxic-cell radiosensitizer Ro-07-0582. When 1 mg/g body wt. was given before a single dose of X-rays, a dose-enhancement ratio of 2-0 was found. When the drug was given immediately after irradiation, a large cytotoxic effect was observed, equivalent to an enhancement ratio of 1-3. These results were confirmed by determining the X-ray doses required for the local control of 50% of the tumours at 80 days after irradiation. The capacity of the tumour for repair of sublethal X-ray injury within 24 h was similar to that for several normal tissues.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 869984      PMCID: PMC2025355          DOI: 10.1038/bjc.1977.69

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  The response of a transplantable tumor to fractionated irradiation. 1. X rays and the hypoxic cell radiosensitizer Ro-07-0582.

Authors:  J Denekamp; S R Harris
Journal:  Radiat Res       Date:  1976-04       Impact factor: 2.841

2.  Selective radiosensitization of the hypoxic cells of mouse tumors with the nitroimidazoles metronidazole and Ro 7-0582.

Authors:  J M Brown
Journal:  Radiat Res       Date:  1975-12       Impact factor: 2.841

3.  Studies of the processes occurring between two fractions in experimental mouse tumors.

Authors:  J Denekamp; S R Harris
Journal:  Int J Radiat Oncol Biol Phys       Date:  1976 Mar-Apr       Impact factor: 7.038

4.  Skin reactions in mice after multifraction x-irradiation.

Authors:  J F Fowler; J Denekamp; C Delapeyre; S R Harris; P W Sheldon
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1974-03

5.  Optimum fractionation in X-ray treatment of C3H mouse mammary tumours.

Authors:  J F Fowler; J Denekamp; P W Sheldon; A M Smith; A C Begg; S R Harris; A L Page
Journal:  Br J Radiol       Date:  1974-11       Impact factor: 3.039

6.  Split-dose recovery in euoxic and hypoxic normal and tumor cells.

Authors:  T L Phillips
Journal:  Radiology       Date:  1972-10       Impact factor: 11.105

7.  The relationship between the 'cell loss factor' and the immediate response to radiation in animal tumours.

Authors:  J Denekamp
Journal:  Eur J Cancer       Date:  1972-06       Impact factor: 9.162

8.  Survival curves for clonogenic cells of a murine keratinizing squamous carcinoma irradiated in vivo or under hypoxic conditions.

Authors:  H B Hewitt; D P Chan; E R Blake
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1967

9.  Biological properties and response to x-rays of first-generation transplants of spontaneous mammary carcinomas in C3H mice.

Authors:  J F Fowler; P W Sheldon; A C Begg; S A Hill; A M Smith
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1975-05

10.  Radiosensitization of C3H mouse mammary tumours by a 2-nitroimidazole drug.

Authors:  P W Sheldon; J L Foster; J F Fowler
Journal:  Br J Cancer       Date:  1974-12       Impact factor: 7.640

View more
  4 in total

1.  Further investigations of the effects of the hypoxic-cell radiosensitizer, Ro-07-0582, on local control of a mouse tumour.

Authors:  P W Sheldon; S A Hill
Journal:  Br J Cancer       Date:  1977-08       Impact factor: 7.640

2.  Hypoxic cell radiosensitizers and local control by X-ray of a transplanted tumour in mice.

Authors:  P W Sheldon; S A Hill
Journal:  Br J Cancer       Date:  1977-06       Impact factor: 7.640

3.  The response of human tumour metastases to radiation and misonidazole.

Authors:  P J Dawen; M J Peckham; G G Steel
Journal:  Br J Cancer Suppl       Date:  1978-06

4.  Regression, recurrence and cure in an irradiated mouse tumour.

Authors:  A S Abdelaal; A H Nias
Journal:  J R Soc Med       Date:  1979-02       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.